Latest P53 Stories
- More than 50 abstracts highlight breadth and depth of Novartis Oncology pipeline and ability to test various combinations early to target multiple pathways EAST HANOVER, N.J., April 3, 2014
Since the dawn of civilization people were searching for clues to longevity and trying to extend human lifespan.
Studies Identify PI3K Pathway Combinations and MYC Driven Cancers SAN DIEGO and NEW TAIPEI CITY, Taiwan, March 27, 2014 /PRNewswire-iReach/ -- Senhwa Biosciences, Inc.
Clinical and Regulatory Plans for Two Lead Products Announced SAN DIEGO, Feb.
Johns Hopkins scientists say a previously known but little studied chemical compound targets and shuts down a common cancer process.
A new study led by University of Kentucky researchers suggests that activating the tumor suppressor p53 in normal cells causes them to secrete Par-4, another potent tumor suppressor protein that induces cell death in cancer cells.
A potential new cancer therapy works by “turning on” a powerful natural tumor suppressor. Raleigh, NC (PRWEB) December 24, 2013 A new study published
A team of scientists at Johns Hopkins and in Texas has identified a handful of genetic mutations in black Americans, in addition to some chemical alterations affecting gene activity, which may help explain why the death rate among African-Americans from the most common form of head and neck cancer continues to hover some 18 percent higher above the death rate of whites with the same cancer.
Certain genetic alterations to the PAX gene family may be responsible for survival disparities seen between African-American and non-Latino white men with head and neck cancer.